Landmark Ideas Series: Karen Copenhaver

Speaker: Karen Copenhaver, at The Linux Foundation

Date: May 1, 2023 at 4:00PM - 5:30PM

Talk Topic: Using Licensing to Maximize Innovation in The Open Source Software Ecosystem.

Karen Copenhaver is listed in The International Who's Who of Internet & e-Commerce Lawyers, Chambers USA, Who’s Who Legal, Best Lawyers in America and among the top 50 women Massachusetts Super Lawyers. Ms. Copenhaver was named "Lawyer of the Year" in Boston for information technology law by Best Lawyers 2018. She was named a 2013 “Top Woman of Law” by Massachusetts Lawyers Weekly. She was also named the 2016 Boston “Lawyer of the Year” for Information Technology Law by Best Lawyers, a designation she also received in 2013 for Copyright Law and in 2014 and 2012 for Information Technology Law, and has been named in The Legal 500 for technology transactions. Ms. Copenhaver is only the 5th lawyer ever to receive Mass High Tech'sprestigious “Mass High Tech All-Stars Award,” which honors the thought leaders and innovators throughout the New England technology sector. She has been chosen by Intellectual Asset Management magazine as one of the world’s top IP strategists in their feature “IAM 250 — A Guide to the World’s Leading IP Strategists.” She has also been named a top patent and technology licensing practitioner in IAM Licensing 250 and a world’s leading patent practitioner in IAM Patent 1000. She has been recognized by Managing Intellectual Property as an “IP Star” and among the “Top 250 Women in IP” nationwide.


Publications

Hopper RK, Abman SH, Elia EG, Avitabile CM, Yung D, Mullen MP, Austin ED, Bates A, Handler SS, Feinstein JA, Ivy DD, Kinsella JP, Mandl KD, Raj JU, Sleeper LA, . Pulmonary Hypertension in Children with Down Syndrome: Results from the Pediatric Pulmonary Hypertension Network Registry. The Journal of pediatrics 2022.

Wang X, Zhang HG, Xiong X, Hong C, Weber GM, Brat GA, Bonzel CL, Luo Y, Duan R, Palmer NP, Hutch MR, Gutiérrez-Sacristán A, Bellazzi R, Chiovato L, Cho K, Dagliati A, Estiri H, García-Barrio N, Griffier R, Hanauer DA, Ho YL, Holmes JH, Keller MS, Klann MEng JG, L'Yi S, Lozano-Zahonero S, Maidlow SE, Makoudjou A, Malovini A, Moal B, Moore JH, Morris M, Mowery DL, Murphy SN, Neuraz A, Yuan Ngiam K, Omenn GS, Patel LP, Pedrera-Jiménez M, Prunotto A, Jebathilagam Samayamuthu M, Sanz Vidorreta FJ, Schriver ER, Schubert P, Serrano-Balazote P, South AM, Tan ALM, Tan BWL, Tibollo V, Tippmann P, Visweswaran S, Xia Z, Yuan W, Zöller D, Kohane IS, Avillach P, Guo Z, Cai T, . SurvMaximin: Robust federated approach to transporting survival risk prediction models. Journal of biomedical informatics 2022.

Torous J, Stern AD, Bourgeois FT. Regulatory considerations to keep pace with innovation in digital health products. NPJ digital medicine 2022.

Levy S, Wisk LE, Minegishi M, Ertman B, Lunstead J, Brogna M, Weitzman ER. Association of Screening and Brief Intervention With Substance Use in Massachusetts Middle and High Schools. JAMA network open 2022.

Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Co-existing alterations of MHC class I antigen presentation and IFNγ signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy. Cancer immunology research 2022.